-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65

Benzinga·08/11/2026 14:50:45
Listen to the news
JP Morgan analyst Hardik Parikh maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and lowers the price target from $75 to $65.